Author

G. Hoermann

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 4

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 4 Assay:bulk RNA-seq· 3 Research Focus:cell type annotation· 3 Research Focus:differential expression· 3 Organism:human· 3 Research Focus:cancer & tumor microenvironment· 2 Organism:mouse· 2 Research Focus:cell signaling & trafficking· 1

Frequent Co-Authors

R. Moriggl· 4 shared H. A. Neubauer· 3 shared B. Maurer· 2 shared G. Egger· 2 shared J. Pencik· 2 shared M. Schlederer· 2 shared S. D. Turner· 2 shared S. Tangermann· 2 shared

Activity by Year

2019-2024 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 33 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

4 shared papersCancer Biology

R. Moriggl

Mutual co-authors in cluster

Author profile →

4 papers

Recent·Most cited

A lineage-specific STAT5BN642H mouse model to study NK-cell leukemia

K. Klein, S. Kollmann, J. List, A. Hiesinger, J. Kender, M. Rhandawa, J. Trifinopoulos, B. Maurer, R. Grausenburger, R. Moriggl, T. Ruelicke, A. Witalisz-Siepracka, W. Walter, G. Hoermann, V. Sexl, D. Gotthardt

This paper creates a mouse model with a STAT5BN642H mutation to study NK-cell leukemia and finds it leads to both indolent and aggressive forms of the disease.

Blood · Jun 13, 2024Peer-reviewedCancer Biology

STAT5 Gain-of-Function Variants Promote Precursor T-Cell Receptor Activation to Drive T-Cell Acute Lymphoblastic Leukemia

T. Suske, H. Sorger, F. Ruge, N. Prutsch, M. W. Zimmerman, T. Eder, B. Maurer, C. Wagner, S. Schoenefeldt, K. Spirk, A. Pichler, T. Pemovska, C. Schweicker, D. Poeloeske, D. Jungherz, , R. Moriggl

This study identifies STAT5 gain-of-function mutations as drivers of T-ALL by promoting pre-TCR signaling and shows therapeutic targeting potential with STAT3/5 or ZAP70 inhibitors.

bioRxiv · Dec 21, 2022 · PreprintCancer Biology

STAT3 restricts prostate cancer metastasis and antiandrogen resistance by controlling LKB1/CREB signaling pathway

J. Pencik, C. Philippe, M. Schlederer, M. Pecoraro, S. Grund-Groeschke, W. J. Li, A. Tracz, I. Heidegger, S. Lagger, K. Trachtova, M. Oberhuber, E. Heitzer, O. Osman, H. A. Neubauer, B. Wingelhofer, , C. McKinney

This study identifies STAT3's role in restricting prostate cancer metastasis and antiandrogen resistance by regulating the LKB1/CREB signaling pathway in mouse models and human patients.

bioRxiv · Aug 25, 2022 · PreprintCancer Biology

Thyroid and androgen receptor signaling are antagonized by CRYM in prostate cancer

O. Aksoy, J. Pencik, M. Hartenbach, A. A. Moazzami, M. Schlederer, T. Balber, B. Mazumder, J. Whitchurch, C. J. Roberts, M. Susani, M. Mitterhauser, R. Marculescu, G. Kramer, S. D. Turner, S. Hartenbach, , L. Kenner

This study shows that CRYM antagonizes thyroid and androgen signaling in prostate cancer and correlates with prognosis and PET imaging biomarkers.

bioRxiv · Dec 19, 2019Cancer Biology